Chemical warfare agent detection technology used to treat lung diseaseA new technique based on the same technology used to detect chemical warfare agents and explosives is being employed by scientists at The University of Manchester to treat hospital patients with lung disease.
Dr Paul Thomas and a team of researchers are using a sensor, commonly used to detect explosives at airports, to develop a new way of diagnosing lung disease.
The technology is currently being tested at Wythenshawe Hospital's North West Lung Research Centre (NWLRC). The aim is to produce a device which will enable doctors to monitor patients with lung or respiratory conditions by simply asking them to breathe into it.
Dr Paul Thomas from the University's School of Chemical Engineering and Analytical Science, who is leading the research, said: "Our vision is that one day we will be able to detect a previously undetectable tumour metabolising inside a human lung simply by asking a patient to breathe into a device like this. For now our aim to use the microDMx sensor to develop better instruments which will improve patient care and treatment.
"The potential is such that we will not only be able to provide more accurate diagnosis, but we will also be able to tailor treatments to the individual. For instance, if a patient is taking steroids for asthma, we would be able determine whether they were being given the right amount of steroids from the molecules in their breath which relate to the severity of the inflammation in their lungs."
NWLRC Consultant Dr Dave Singh, said: "This research could make dramatic improvements to the detection of lung diseases. We are really excited about the future possibilities for diagnosing diseases, and monitoring the response to treatment."
The microDMx sensor can be used to detect and analyse a broad spectrum of molecules associated with different conditions with extreme sensitivity. It can also be configured to block out molecules produced by common ailments such as sore throats or chesty coughs which may interfere with the accuracy of data.
"What is unique about this sensor, and the use of the microDMx technology, is the fact that it can be configured to not just analyse one disease or condition, but it has the potential to be used to analyse a broad spectrum of conditions from asthma, to cancer and metabolic disorders such as diabetes," says Dr Thomas.
Dr Thomas' research will form part of a new National Initiative in Ion Mobility Spectrometry (NIIMS), which aims to explore the use of IMS measurement within the pharmaceutical and biomedical fields. Alongside Professor Colin Creaser from Nottingham Trent University he will lead a consortium of experts and industrial partners, who will be evaluating DMS and IMS potential in areas such as high-speed separations of complex mixtures and structural characterisation of pharmaceuticals and biomolecules.
Pharmaceutical giants GlaxoSmithKline and AstraZeneca have already pledged their support for the NIIMS initiative, along with Micromass UK, committing £530K.
For further information:
Simon Hunter, Media Relations Officer, telephone: 0161 2758387
Notes to Editors:
Published on PsychCentral.com. All rights reserved.